Loading…
Back to Compound Explorer
Dehydrotumulosic Acid
PreliminaryMechanism of Action
Dehydrotumulosic acid demonstrates superior anti-hyperglycemic activity compared to other Poria triterpenoids by increasing insulin sensitivity through a mechanism that is explicitly independent of PPAR-γ pathway activation, distinguishing it from thiazolidinedione drugs (rosiglitazone, pioglitazone). This represents a potentially novel insulin-sensitizing mechanism. Anti-inflammatory activity occurs through direct inhibition of phospholipase A2 (PLA2) enzyme, preventing arachidonic acid release from membrane phospholipids and blocking downstream prostaglandin and leukotriene synthesis. Additionally stimulates IFN-γ secretion by spleen cells, enhancing cellular immune responses.
Research Notes
PoriaMushroom
In vivo studies in db/db diabetic mice showed glucose-lowering activity comparable to metformin, with dehydrotumulosic acid demonstrating significantly superior efficacy compared to pachymic acid and dehydrotrametenolic acid. Anti-inflammatory activity was confirmed in mouse ear edema models with significant reduction in inflammatory swelling. PLA2 inhibition was demonstrated through enzyme kinetics assays. No human clinical trials have been conducted on isolated dehydrotumulosic acid.
Found In 1 Herb
3D Molecular Structure
Lanostane triterpenoid
Drag to rotate · Click atoms to explore
Dehydrotumulosic Acid
Lanostane triterpenoidModified terpenes with diverse biological activities
Representative pattern: C₁₀H₁₆O
Atoms
Carbon
Oxygen
Hydrogen
Related Compounds (Lanostane triterpenoid)
Live Research
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare practitioner before using any herbal product.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This content is for educational purposes only and is not a substitute for professional medical advice.